Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $57,325.20 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 61,640 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $0.93, for a total transaction of $57,325.20. Following the completion of the transaction, the insider directly owned 5,538,600 shares in the company, valued at approximately $5,150,898. The trade was a 1.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
• On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $89,131.98.
• On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total value of $44,329.21.
• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $63,623.40.
• On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total transaction of $57,312.60.
• On Friday, November 7th, Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $65,886.92.
• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $0.92 on Thursday. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The stock has a market cap of $44.88 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. The stock’s 50-day moving average is $1.55 and its 200 day moving average is $1.33. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, sell-side analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares in the last quarter. MPM Asset Management LLC boosted its holdings in Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares in the last quarter. Nuveen LLC purchased a new position in Werewolf Therapeutics during the 1st quarter valued at $71,000. MPM Bioimpact LLC raised its holdings in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter worth $92,000. 64.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on HOWL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. JMP Securities lowered their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Finally, Bank of America lowered their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.